Letter regarding "Prevalence of growth hormone deficiency in previously GH-treated young adults with Prader-Willi syndrome" by Donze et al
Clin Endocrinol (Oxf)
.
2019 Oct;91(4):578-579.
doi: 10.1111/cen.14047.
Epub 2019 Jun 26.
Authors
Charlotte Höybye
1
2
,
Maithé Tauber
3
,
Moris A Angulo
4
,
Urs Eiholzer
5
,
Daniel J Driscoll
6
,
Suzanne B Cassidy
7
,
Antony J Holland
8
;
Clinical & Scientific Advisory Board of The International Prader-Willi Syndrome Organisation
Affiliations
1
Patient Area Endocrinology and Nephrology, Karolinska University Hospital, Stockholm, Sweden.
2
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
3
Hôpital des enfants, Centre de référence du Syndrome de Prader-Willi, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
4
Pediatric Endocrinology, NYU Winthrop Hospital, Mineola, New York.
5
Centre for Pediatric Endocrinology, University of Zürich, Zürich, Switzerland.
6
Chair, IPWSO Clinical & Scientific Advisory Board, University of Florida College of Medicine, Gainesville, Florida.
7
Past President IPWSO, Division of Medical Genetics, University of California, San Francisco, California.
8
President IPWSO, Department of Psychiatry, University of Cambridge, Cambridge, UK.
PMID:
31215054
DOI:
10.1111/cen.14047
No abstract available
Keywords:
GH deficiency; GH treatment; PWS adults.
Publication types
Letter
Comment
MeSH terms
Human Growth Hormone*
Humans
Obesity
Prader-Willi Syndrome*
Prevalence
Young Adult
Substances
Human Growth Hormone